3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Dexamethasone
8
daratumumab
5
Lenalidomide
5
Bortezomib
5
Trimethoprim, Sulfamethoxazole Drug Combination
4
Thalidomide
4
Cyclophosphamide
4
gamma-Globulins
3
Ciprofloxacin
3
carfilzomib
2
Melphalan
2
Immunoglobulins, Intravenous
2
Calcium Dobesilate
2
Amoxicillin-Potassium Clavulanate Combination
2
trametinib
1
tanespimycin
1
pomalidomide
1
pazopanib
1
fludarabine
1
dabrafenib
1
cobimetinib
1
Whole-Body Irradiation
1
Vemurafenib
1
Stem Cell Transplantation
1
Rivaroxaban
1
Radiotherapy
1
Radiation
1
Pharmaceutical Preparations
1
Mesna
1
MAGEA3 protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Clavulanic Acid
×
Plasma cell
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled